Cipla Limited (LUX:CIPLA)

Luxembourg flag Luxembourg · Delayed Price · Currency is EUR · Price in USD
14.70
-0.10 (-0.68%)
At close: Feb 6, 2026
Market Cap10.04B -22.9%
Revenue (ttm)2.65B +4.7%
Net Income430.93M -8.9%
EPS0.53 -8.9%
Shares Outn/a
PE Ratio23.29
Forward PE23.89
Dividend0.12 (0.84%)
Ex-Dividend DateJun 26, 2025
Volumen/a
Average Volumen/a
Openn/a
Previous Close14.80
Day's Rangen/a
52-Week Range14.30 - 18.90
Betan/a
RSI34.59
Earnings DateJan 23, 2026

About Cipla

Cipla Limited, together with its subsidiaries, manufactures, develops, sells, and distributes pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New Ventures segments. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, such as MI, angina, heart disease, pulmonary disease, kidney failure, Alzheimer’s disease, hypertension, arrhythmia, lipid abnormalities and diabetes, obe... [Read more]

Industry Pharmaceutical Preparations
Founded 1935
Employees 30,313
Stock Exchange Luxembourg Stock Exchange
Ticker Symbol CIPLA
Full Company Profile

Financial Performance

In fiscal year 2025, Cipla's revenue was 272.67 billion, an increase of 6.78% compared to the previous year's 255.37 billion. Earnings were 52.73 billion, an increase of 27.93%.

Financial numbers in INR Financial Statements